Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Feb 9:5:F1000 Faculty Rev-152.
doi: 10.12688/f1000research.7424.1. eCollection 2016.

Recent Advances in Understanding and Managing Tourette Syndrome

Affiliations
Review

Recent Advances in Understanding and Managing Tourette Syndrome

Mary Ann Thenganatt et al. F1000Res. .

Abstract

Tourette syndrome (TS) is a neurologic and behavioral disorder consisting of motor and phonic tics with onset in childhood or adolescence. The severity of tics can range from barely perceptible to severely impairing due to social embarrassment, discomfort, self-injury, and interference with daily functioning and school or work performance. In addition to tics, most patients with TS have a variety of behavioral comorbidities, including attention deficit hyperactivity disorder and obsessive-compulsive disorder. Studies evaluating the pathophysiology of tics have pointed towards dysfunction of the cortico-striato-thalamo-cortical circuit, but the mechanism of this hyperkinetic movement disorder is not well understood. Treatment of TS is multidisciplinary, typically involving behavioral therapy, oral medications, and botulinum toxin injections. Deep brain stimulation may be considered for "malignant" TS that is refractory to conventional therapy. In this review, we will highlight recent developments in the understanding and management strategies of TS.

Keywords: Tourette syndrome; behaviour; neurology.

PubMed Disclaimer

Conflict of interest statement

Competing interests: Dr. Thenganatt has no relevant disclosures. Dr. Jankovic has served as a consultant or as an advisory committee member for Allergan, Inc; Auspex Pharmaceuticals, Inc; Teva Pharmaceutical Industries Ltd.

No competing interests were disclosed.

References

    1. Jankovic J, Gelineau-Kattner R, Davidson A: Tourette's syndrome in adults. Mov Disord. 2010;25(13):2171–2175. 10.1002/mds.23199 - DOI - PubMed
    1. Patel N, Jankovic J, Hallett M: Sensory aspects of movement disorders. Lancet Neurol. 2014;13(1):100–112. 10.1016/S1474-4422(13)70213-8 - DOI - PMC - PubMed
    1. Baizabal-Carvallo JF, Jankovic J: Speech and voice disorders in patients with psychogenic movement disorders. J Neurol. 2015;262(11):2420–2424. 10.1007/s00415-015-7856-7 - DOI - PubMed
    1. Thenganatt MA, Jankovic J: Psychogenic movement disorders. Neurol Clin. 2015;33(1):205–224. 10.1016/j.ncl.2014.09.013 - DOI - PubMed
    1. Baizabal-Carvallo JF, Jankovic J: The clinical features of psychogenic movement disorders resembling tics. J Neurol Neurosurg Psychiatry. 2014;85(5):573–575. 10.1136/jnnp-2013-305594 - DOI - PubMed

LinkOut - more resources